0000000000860849

AUTHOR

Stephan Walcher

showing 2 related works from this author

Maintenance treatment for opioid dependence with slow‐release oral morphine: a randomized cross‐over, non‐inferiority study versus methadone

2012

Aims To compare the efficacy of slow-release oral morphine (SROM) and methadone as maintenance medication for opioid dependence in patients previously treated with methadone. Design Prospective, multiple-dose, open label, randomized, non-inferiority, cross-over study over two 11-week periods. Methadone treatment was switched to SROM with flexible dosing and vice versa according to period and sequence of treatment. Setting Fourteen out-patient addiction treatment centres in Switzerland and Germany. Participants Adults with opioid dependence in methadone maintenance programmes (dose ≥50 mg/day) for ≥26 weeks. Measurements The efficacy end-point was the proportion of heroin-positive urine samp…

AdultMaleNarcoticsMethadone maintenanceretention ratePopulationslow-release oral morphineAdministration OralMedicine (miscellaneous)Maintenance ChemotherapyMedication AdherencemethadoneOpiate Substitution TreatmentmedicineHumanseducationMorphine Derivativeseducation.field_of_studyCross-Over StudiesMorphinemaintenance treatmentCodeinebusiness.industryCodeineResearch ReportsOpioid use disorderOpiate Substitution TreatmentMiddle AgedOpioid-Related Disordersmedicine.diseaseCrossover studyPsychiatry and Mental healthTreatment OutcomeOpioidDelayed-Action PreparationsAnesthesiaFemaleDose–responsebusinessopioid addictionMethadonemedicine.drugAddiction
researchProduct

Hepatitis C virus: Current steps toward elimination in Germany and barriers to reaching the 2030 goal

2021

Abstract Hepatitis C virus (HCV) affects over 70 million people globally, with an estimated 399 000 HCV‐related deaths in 2016. The World Health Organization (WHO) has set a goal to eliminate HCV by 2030. Despite the availability of direct‐acting antivirals—highly effective and well‐tolerated therapies for HCV—many patients infected with HCV in Germany have not initiated treatment, including a majority of those who are aware of their positive diagnosis. Barriers to screening, diagnosis, and treatment are major factors taking many countries off track for HCV elimination by 2030. Identifying country‐specific barriers and challenges, particularly in at‐risk populations such as people who injec…

medicine.medical_specialtybusiness.industryHepatitis C virusbarriersRReviewsvirus diseasesReviewGeneral MedicineHepatitis Chigh‐risk groupsmedicine.diseasemedicine.disease_causeHepatitis CHcv eliminationWorld healthdigestive system diseasesMen who have sex with meneliminationFamily medicineGermanyMedicineMedicinebusinessGood practiceHealth Science Reports
researchProduct